Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE dendritic cell therapy plus surgery for resectable epithelioid mesothelioma
NL-OMON59409Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of TriMix-DC in pleural mesothelioma, sponsored by Erasmus MC. Started Aug 2024; status: recruiting.
02
Drugs
TriMix-DC
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON59409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59409.